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Implications for practice and research 
Further exploration is needed within the time period of 1–6 months following a suicide attempt to 
analyse the support required to identify reattempters. 
 
Further research is required to examine the impact and effectiveness of psychological interventions 
on suicide attempters. Does this help to reduce suicide reattempts more than pharmacological 
interventions? 
 
Context 
Suicide is a global priority.1 It is a term commonly associated with a mental health disorder and is 
synonymous to diagnoses such as personality disorder and depression.2 There is no pharmacological 
treatment to stop people from trying to end their lives. However, there is medication that can treat 
the feelings and symptoms experienced by suicide attempters. Medication works on receptors and 
neurotransmitters and does not deal with the underlying emotions that can lead to suicide attempts. 
Suicide is always an emotive subject, and even now it is still an area that is under-researched,3 and 
analysing statistics can demonstrate the need for further research. 
 
Methods 
The research design has used a longitudinal approach to analyse why people reattempt suicide, by 
acknowledging that if a person has attempted suicide, then this is a high predictor that they will try it 
again, due to the unsuccessful preceding attempt. The cohort was recruited from an outpatient 
clinic, with all prospective participants having recently attempted suicide. Participants’ 
sociodemographic data were collected and presented as part of the sample descriptors, which 
highlight the potential social vulnerabilities. Current treatment options in the form of 
pharmacological interventions were examined in an effort to try to seek a rationale for behaviours 
and existing treatments.4 The authors followed each patient from inclusion in the study to the next 
attempt at suicide or for a period of 2 years. 
 Findings 
Through the cohort study it was found that 70 out of the initial 371 participants reattempted suicide. 
All participants were receiving pharmacological treatment, in the form of either antipsychotics, 
anxiolytics or antidepressants. The trends in these findings were of diagnosis and attempt style. The 
findings were able to show a risk period following the initial attempt and the increased risk of a 
further attempt. There was an increased risk in the initial 6 months after an attempt, with 20% of the 
cohort reattempting suicide within the first month. This clearly calls for a more intense monitoring 
period.5 
 
Commentary 
This prospective study included 371 participants of ages ranging from 18 to 91 and data were 
collected between 2013 and 2016. The manner in which the suicide was attempted was also 
examined to explore the prevalence and the preference within this cohort of how they attempted to 
end their lives. The statistics present the sociodemographic data, including the preferred method of 
suicide attempt, and using the Kaplan-Meier survival curve, when the reattempters enter a 
vulnerable period to reattempt. It is declared that all the participants in the study were in receipt of 
some form of psychopharmacology. 
 
A question to be posed is what other interventions, if any, were the participants in receipt of? This 
was not a consideration of this study due to the focus being placed on psychopharmacological 
treatment.4 5 Guidelines2 have recommended adjunct treatment with psychological therapies and 
psychopharmacology when supporting people who experience suicidal behaviours and in helping 
them to reduce the severity and intent to end life. It has been clearly demonstrated that 
psychopharmacological interventions do not assist with reducing reattempts of suicide.6 A 
recognition that is reached in this study, as all the participants are currently receiving and are 
compliant with their medication regimen. The researchers do recognise the dropout rate was quite 
significant, and this was acknowledged in the study’s limitations and overall impact on validity. 
 
The community that works with people who are frequent suicide attempters needs to have many 
skills in order to be responsive to the emotional needs and to be flexible in providing skills of support 
to this demographic. 
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